HCV drug combo linked to side effects after liver transplant

05/16/2013 | Aidsmap

Treating hepatitis C-positive patients who underwent a liver transplant with a combination of three drugs -- pegylated interferon, ribavirin and telaprevir -- increased sustained viral response rates even for difficult cases, but adverse events were also common, according to findings presented at a liver meeting. Among the adverse events were the need for transfusions to address blood cell deficiencies. The study evaluated data from six U.S. centers.

View Full Article in:

Aidsmap

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ